Prohibiting Abortion Industry’s Lucrative Loopholes Act

HR 727 amends federal law to expand the definition of "valuable consideration" in transactions involving human fetal tissue. The bill specifically adds provisions to prohibit payments, waived fees, canceled debts, or free/discounted services related to tissue transportation, processing, storage, or implantation. This directly affects medical providers, laboratories, and facilities handling fetal tissue by restricting how they can receive compensation for these services. The key change clarifies that even indirect financial benefits, like reduced charges or waived costs, would be considered prohibited "valuable consideration."